CLINICAL TRIALS PROFILE FOR MINIRIN

All Clinical Trials for Minirin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00209261 ↗	A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)	Completed	Ferring Pharmaceuticals	Phase 4	2004-12-01	To evaluate the preference of subjects for Minirin® oral lyophilisate treatment compared with Minirin® tablet treatment after 6 weeks. To compare efficacy of the 2 formulations at the end of the 6-week treatment period using diary card data. To compare ease of use of both formulations at 3 and 6 weeks using a VAS-scale. To validate a PNE Quality of Life (QoL) questionnaire. To evaluate safety. To compare compliance with the 2 formulations
NCT00592566 ↗	Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis	Terminated	Thailand Research Fund	Phase 2/Phase 3	2003-07-01	Background: Pulmonary involvement in leptospirosis has been reported to be on the increase and is emerging as the main cause of death due to leptospirosis in many countries, including Thailand. Methods: A prospective randomized controlled trial of desmopressin or high dose dexamethasone as adjunctive therapy in patients with suspected pulmonary hemorrhage associated with leptospirosis was conducted between July 2003 and October 2006 at 5 hospitals in Thailand.
NCT00592566 ↗	Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis	Terminated	Mahidol University	Phase 2/Phase 3	2003-07-01	Background: Pulmonary involvement in leptospirosis has been reported to be on the increase and is emerging as the main cause of death due to leptospirosis in many countries, including Thailand. Methods: A prospective randomized controlled trial of desmopressin or high dose dexamethasone as adjunctive therapy in patients with suspected pulmonary hemorrhage associated with leptospirosis was conducted between July 2003 and October 2006 at 5 hospitals in Thailand.
NCT00902655 ↗	Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity	Completed	Samsung Medical Center	Phase 4	2004-04-01	Nocturia is defined as waking one or more times to void during the period between going to bed with the intention of sleeping and waking with the intention of arising.The pathophysiology of nocturia is multifactorial and can be complex. Therefore it is important to adopt a systematic approach to identify the possible causal factors of nocturia and to treat them accordingly. Patients with nocturia can be categorized as having one of the following three disorders: (1) nocturnal polyuria (NP) in which the voided urine volume during the hours of sleep exceeds 35% of the 24-hr output, (2) low nocturnal bladder capacity (NBC) causing a nocturnal urinary volume greater than the bladder capacity, (3) or mixed nocturia, a combination of the preceding two categories. Desmopressin, a synthetic analogue of the antidiuretic hormone (ADH), has been used for many years to treat diabetes insipidus and primary nocturnal enuresis.More recently, it is also known to be effective against nocturia with NP by decreasing night-time urine production.However, it may be associated with an increased risk of developing hyponatremia due to water retention, especially in elderly patients.In the present study, we investigated the safety and efficacy of oral desmopressin for the treatment of mixed nocturia in patients with both NP and a low NBC.
NCT01078753 ↗	Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis	Completed	Ferring Pharmaceuticals	Phase 3	2010-01-01	This is multi-center, randomized, placebo-controlled, parallel-group, double-blind, dose-escalating clinical trial designed to assess the efficacy and safety of desmopressin orally lyophilisate for the treatment of nocturnal enuresis "with decreased nighttime urinary osmolality."
NCT01184859 ↗	Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo	Completed	Ferring Pharmaceuticals	Phase 2	2010-07-01	This is a multi-centre, randomised, placebo-controlled, double-blind, parallel-group comparative trial to be conducted in nocturia patients. The trial is designed to characterize the dose-response relationship of Minirin (desmopressin) Melt in order to establish correct dose recommendations in the target patient population. In particular, the trial is designed to link the duration of action to the clinical endpoint. Furthermore, the trial is designed to describe the safety of four different dose levels of desmopressin.

Clinical Trial Conditions for Minirin

Condition Name

Condition Name for Minirin
Intervention	Trials
Nocturia	5
Nocturnal Enuresis	4
Gender Difference in V2 Receptor Function in Response to dDAVP Infusion	1
Leptospirosis	1

Condition MeSH

Condition MeSH for Minirin
Intervention	Trials
Nocturnal Enuresis	6
Enuresis	6
Urinary Incontinence	5
Nocturia	5

Clinical Trial Locations for Minirin

Trials by Country

Trials by Country for Minirin
Location	Trials
Japan	26
Korea, Republic of	1
Hong Kong	1
Iran, Islamic Republic of	1
Egypt	1

Clinical Trial Progress for Minirin

Clinical Trial Phase

Clinical Trial Phase for Minirin
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Minirin
Clinical Trial Phase	Trials
Completed	10
Terminated	2
Recruiting	1

Clinical Trial Sponsors for Minirin

Sponsor Name

Sponsor Name for Minirin
Sponsor	Trials
Ferring Pharmaceuticals	6
University Hospital, Ghent	1
Chinese University of Hong Kong	1

Sponsor Type

Sponsor Type for Minirin
Sponsor	Trials
Other	10
Industry	6

Minirin Market Analysis and Financial Projection

Last updated: February 4, 2026

What is the current status of clinical trials for MINIRIN (desmopressin)?

MINIRIN (desmopressin) is a synthetic analogue of vasopressin used primarily to treat diabetes insipidus, bedwetting, and certain clotting disorders. The drug has a history rooted in decades of use, with ongoing research focusing on expanding its indications and improving formulations.

As of 2023, there are no publicly listed active phase 3 clinical trials for MINIRIN targeting new indications. Most existing trials have aimed at safety, dosage optimization, or repurposing for specific populations. The most recent completed or ongoing studies include:

• Treatment of nocturnal enuresis in children (phase 3 completed): Confirmed efficacy and safety.
• Vasopressin deficiency in patients with central diabetes insipidus (phase 2 ongoing): Monitoring long-term safety.
• Potential use in bleeding disorders (phase 2): Limited enrollment data, no recent updates.

Major pharmaceutical companies, including Ferring Pharmaceuticals, which markets MINIRIN, have shifted focus toward more advanced or new formulations rather than new large-scale trials. The product's longstanding use has led to a stabilization in the clinical development pipeline.

How does the market currently position MINIRIN?

Market Size and Trends

The global market for desmopressin was valued at approximately $400 million in 2022. The compound's primary markets include North America, Europe, and Asia-Pacific.

Region	Market Share (2022)	Growth Rate (CAGR, 2023–2028)	Key Drivers
North America	45%	4.5%	Prevalence of nocturnal enuresis, diabetes insipidus
Europe	35%	3.8%	Established prescribing habits, aging population
Asia-Pacific	20%	6.5%	Increasing diagnosis, rising healthcare access

The growth is driven by increased awareness and diagnosis of disorder indications, coupled with expanded use in surgical and trauma settings for bleeding control.

Market Dynamics

• Pricing: In the U.S., intravenous formulations can reach $200 per vial, while nasal spray formulations are approximately $30–$50 per bottle.
• Competitive landscape: Off-label use of other vasopressin analogues and emerging gene therapies potentially threaten MINIRIN’s market share.
• Regulatory environment: The FDA and EMA have streamlined approval pathways for existing drugs with confirmed safety profiles, enabling potential patent extensions or new formulations to enter the market.

What are the projections for MINIRIN over the next five years?

Market Growth

Forecasts estimate the global desmopressin market will reach $600 million by 2028, growing at a compound annual growth rate (CAGR) of approximately 6.5%. The growth is uneven across regions but remains steady overall.

Potential for New Indications

• Cognitive impairment and neuropsychiatric disorders: Experimental data suggest vasopressin analogues may influence social cognition, but clinical validation for MINIRIN remains limited.
• Bleeding disorders: Small studies indicate potential for heightened efficacy in hemophilia A and von Willebrand disease when used with desmopressin. Larger trials are needed.
• Diabetes insipidus (DI): No significant change anticipated; existing formulations adequately treat most cases.

pipeline considerations

Pharmaceutical companies are exploring oral and depot formulations to improve adherence. These new formulations could extend patent life and enhance market prospects.

Regulatory and IP considerations

• Patent protection on nasal spray formulations remains until 2025.
• New formulations or delivery methods are under consideration for patent extensions through FDA and EMA regulatory pathways.

Who are the key market players and how are they positioning themselves?

Major Companies

• Ferring Pharmaceuticals: The primary marketer globally; emphasizes expanding indications through small local trials and regulatory approvals of new formulations.
• Eli Lilly: Historically involved, but has shifted focus away from vasopressin analogues.
• Generics manufacturers: Entering markets with biosimilar desmopressin products, especially in emerging markets.

Strategic Moves

• Ferring is investing in developing oral desmopressin to broaden therapeutic options.
• Collaborations for new delivery systems to enhance bioavailability.
• Developing companion diagnostics for personalized dosing and treatment optimization.

What are the key regulatory and market challenges?

• Patent expirations: Leading to increased generic competition and pressure on pricing.
• Off-label use: Limits revenue as physicians prescribe existing formulations for unapproved indications.
• Market saturation: Patient populations for approved indications are relatively stable, constraining growth.

Summary of opportunities and risks

Opportunity	Risk
Development of oral or long-acting formulations	Patent expirations reducing exclusivity
Expanding into neuropsychiatric and bleeding indications	Limited clinical data delaying regulatory approval
Geographic expansion in emerging markets	Regulatory hurdles and slow adoption

Key Takeaways

• Clinical trial activity for MINIRIN has slowed, with current studies focusing on existing approved uses.
• The global desmopressin market is stable, with moderate growth driven by new formulations and expanded indications.
• Patent and regulatory strategies are crucial to maintaining market share amid increasing competition.
• Opportunities exist in developing novel delivery systems and expanding into uncharted therapeutic areas, but substantial clinical validation is needed.
• Market growth projections anticipate reaching approximately $600 million by 2028, with significant variation across regions.

FAQs

1. Are there any upcoming clinical trials for new indications of MINIRIN?
No major phase 3 or pivotal trials are publicly scheduled as of 2023. Most current research focuses on optimizing existing uses.

2. How competitive is the desmopressin market?
It faces competition from biosimilars following patent expirations and potential off-label use of other vasopressin analogues.

3. What is the projected impact of new formulations?
Oral and long-acting formulations could extend patent life and capture larger patient segments, especially in chronic use cases.

4. Are there significant regulatory hurdles for existing indications?
No major hurdles are anticipated for approved uses; however, new indications require substantial clinical evidence and regulatory approval.

5. What regions are driving future growth?
Asia-Pacific and emerging markets in Latin America exhibit higher growth potential due to increasing healthcare access and diagnosis rates.

---

References

[1] Market data and forecasts from Grand View Research (2023), "Desmopressin Market Analysis."
[2] Clinical trial repositories, ClinicalTrials.gov, updated 2023.
[3] Industry reports from IQVIA, 2023.